Compare J B Hunt Transport Services Inc (JBHT) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Moderna, Inc. — how do they compare? J B Hunt Transport Services Inc trades at $228.12 (market cap $21.45B), while Moderna, Inc. trades at $213.82 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 3.7× J B Hunt Transport Services Inc's market cap, and J B Hunt Transport Services Inc pays a 0.79% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold J B Hunt Transport Services Inc for 45 Days and Moderna, Inc. for 59 Days on average.
| JBHT | MRNA | |
|---|---|---|
Market Cap | $21.45B | $78.65B |
Volume | 1,028,680 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $298.41 | $203.46 |
52-Week Low | $137.09 | $22.36 |
Typical Hold Time | 45 Days | 59 Days |
Enterprise Value | $22.59B | $74.80B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $228.99, up 2.85% today, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $12.00B in 2025, with a net income margin of 4.98%, and has beaten EPS estimates in recent quarters. Analyst consensus is a Buy with a $289.40 price target, but news highlights ongoing securities class action investigations.
The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and legal risks pose headwinds. Investors should weigh earnings growth potential against cost pressures and litigation uncertainties for balanced risk-reward assessment.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
